ImmunoGen

NASDAQ: IMGN
$4.62
+$0.14 (+3.1%)
Closing price September 27, 2022
Friday's additional top analyst upgrades and downgrades were on CarMax, Coinbase Global, DocuSign, Enphase Energy, ImmunoGen, Navient, 3M, Virgin Galactic and more.
Monday's additional top analyst upgrades and downgrades included Air Products, Blend Labs, Check Point Software, Deutsche Bank, Huntsman and ImmunoGen.
Wednesday afternoon's analyst upgrades and downgrades included American Water Works, Corvus Pharmaceuticals, ImmunoGen, Lennar, StoneCo and Vertex Energy.
ImmunoGen shares pushed higher to start out the week when the FDA provided an update for the firm’s treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
Friday's top analyst upgrades and downgrades included American Eagle Outfitters, Carvana, General Dynamics, Halliburton, Papa Johns, Snowflake, Splunk, Walmart and Workday.
24/7 Wall St. has compiled a list of some speculative biotech plays that could see gains of up to 300% in the coming months.
Brokerage firm Canaccord Genuity issued some key takeaways on a few different companies at ASCO. 24/7 Wall St. has also included some recent data on the stock.
ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval.
ImmunoGen shares dropped on Monday after the firm released data from its late-stage ovarian cancer study at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Boeing, Booking, Camping World, Domino's Pizza, iRobot, MetLife, Neogen, Southern Copper, Vertex Pharmaceuticals and...
The top analyst upgrades, downgrades and initiations seen on Monday included Alector, Bed Bath & Beyond, Dillard's, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx and Zoetis.
ImmunoGen shares were halved on Friday after the firm reported late-stage results from its ovarian cancer study.
Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and could provide investors with some solid upside potential.
ImmunoGen shares benefited after the company presented data for its latest assessment of mirvetuximab soravtansine at the Society of Gynecologic Oncology annual meeting.
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.